What does LIBRA PHARMA do?

LIBRA PHARMA is a pharmacy in Boechout. Private Limited, started on 16 February 2011, 1 establishment.

What is the address of LIBRA PHARMA?

The registered office of LIBRA PHARMA is located at Vremdesesteenweg 259, 2531 Boechout.

Is LIBRA PHARMA still active?

Yes. According to the CBE (30 October 2026) LIBRA PHARMA is active, legal situation “Normale toestand”, started on 16 February 2011.

Is LIBRA PHARMA registered on Peppol?

Yes, LIBRA PHARMA is registered on the Peppol network with ID 0208:0833903555.

What is the enterprise number of LIBRA PHARMA?

The enterprise number of LIBRA PHARMA is BE0833903555.

When was LIBRA PHARMA founded?

LIBRA PHARMA was founded on 16 February 2011.

Who are the directors of LIBRA PHARMA?

According to the 2025 annual accounts, the directors of LIBRA PHARMA are: Kaatje Bytebier, Esmoreit De Neef.

Is LIBRA PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 February 2011; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did LIBRA PHARMA make in 2025?

LIBRA PHARMA posted a profit after taxes of € 137,007 in financial year 2025.

What is the revenue of LIBRA PHARMA?

As a small company, LIBRA PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 178,051.

LIBRA PHARMA (Private Limited) - Boechout - BE0833903555

Dossier LIBRA PHARMA, printed on 30 October 2026 from databakkes.be/en/0833903555/libra-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 16 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

LIBRA PHARMA from Boechout, company number BE0833903555, closed financial year 2025 with a result of € 137,007 after tax. For that financial year LIBRA PHARMA recorded a gross margin of € 178,051 and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 43,462 to € 137,007. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.

What it is worth Growing

€ 1.2 million

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 137,007

▲ 215% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4,502

▼ 82% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.2 million.

People and assets in 2025

Wage cost

€ 51,858

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 80,581

▲ € 79,054 vs 2024

Of which on lease € 73,026.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.8 million

▲ € 1.7 million vs 2024

€ 147,397 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 9,357

▲ € 7,440 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 75,090

▲ € 65,886 vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 242,875 Gross margin 2022: € 242,875 First fiscal year in the series	€ 85,579 Gross margin 2023: € 85,579 ▼ 65% vs 2022 (€ 242,875) Unfavourable step	€ 71,160 Gross margin 2024: € 71,160 ▼ 17% vs 2023 (€ 85,579) Unfavourable step	€ 178,051 Gross margin 2025: € 178,051 ▲ 150% vs 2024 (€ 71,160) Favourable step	▲ 150%
Profit after taxes	€ 144,233 Profit after taxes 2022: € 144,233 First fiscal year in the series	€ 52,308 Profit after taxes 2023: € 52,308 ▼ 64% vs 2022 (€ 144,233) Unfavourable step	€ 43,462 Profit after taxes 2024: € 43,462 ▼ 17% vs 2023 (€ 52,308) Unfavourable step	€ 137,007 Profit after taxes 2025: € 137,007 ▲ 215% vs 2024 (€ 43,462) Favourable step	▲ 215%
Equity	€ 955,296 Equity 2022: € 955,296 First fiscal year in the series	€ 1,007,604 Equity 2023: € 1,007,604 ▲ 5% vs 2022 (€ 955,296) Favourable step	€ 1,051,065 Equity 2024: € 1,051,065 ▲ 4% vs 2023 (€ 1,007,604) Favourable step	€ 1,187,701 Equity 2025: € 1,187,701 ▲ 13% vs 2024 (€ 1,051,065) Favourable step	▲ 13%
Total debts	€ 770,103 Total debts 2022: € 770,103 First fiscal year in the series	€ 672,029 Total debts 2023: € 672,029 ▼ 13% vs 2022 (€ 770,103) Favourable step	€ 591,834 Total debts 2024: € 591,834 ▼ 12% vs 2023 (€ 672,029) Favourable step	€ 2,377,558 Total debts 2025: € 2,377,558 ▲ € 1.8 million vs 2024 (€ 591,834) Unfavourable step	▲ € 1.8 million
Cash	€ 23,318 Cash 2022: € 23,318 First fiscal year in the series	€ 38,712 Cash 2023: € 38,712 ▲ 66% vs 2022 (€ 23,318) Favourable step	€ 24,350 Cash 2024: € 24,350 ▼ 37% vs 2023 (€ 38,712) Unfavourable step	€ 4,502 Cash 2025: € 4,502 ▼ 82% vs 2024 (€ 24,350) Unfavourable step	▼ 82%
Retained profit	€ 942,896 Retained profit 2022: € 942,896 First fiscal year in the series	€ 995,204 Retained profit 2023: € 995,204 ▲ 6% vs 2022 (€ 942,896) Favourable step	€ 1,038,665 Retained profit 2024: € 1,038,665 ▲ 4% vs 2023 (€ 995,204) Favourable step	€ 1,175,301 Retained profit 2025: € 1,175,301 ▲ 13% vs 2024 (€ 1,038,665) Favourable step	▲ 13%
Bank debt	€ 279,437 Bank debt 2022: € 279,437 First fiscal year in the series	€ 196,179 Bank debt 2023: € 196,179 ▼ 30% vs 2022 (€ 279,437) Favourable step	€ 110,540 Bank debt 2024: € 110,540 ▼ 44% vs 2023 (€ 196,179) Favourable step	€ 1,818,935 Bank debt 2025: € 1,818,935 ▲ € 1.7 million vs 2024 (€ 110,540) Unfavourable step	▲ € 1.7 million
Balance sheet total	€ 1,725,399 Balance sheet total 2022: € 1,725,399 First fiscal year in the series	€ 1,679,633 Balance sheet total 2023: € 1,679,633 ▼ 3% vs 2022 (€ 1,725,399) Unchanged	€ 1,642,900 Balance sheet total 2024: € 1,642,900 ▼ 2% vs 2023 (€ 1,679,633) Unchanged	€ 3,565,259 Balance sheet total 2025: € 3,565,259 ▲ 117% vs 2024 (€ 1,642,900) Unchanged	▲ 117%

Key figures of LIBRA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to LIBRA PHARMA?

What happened at LIBRA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 7, 2026 New annual accounts for financial year 2025: profit of € 137,007 (▲ 215% vs 2024). Source: NBB ↗
2024 Esmoreit De Neef became a director. NBB
2023 Kaatje Bytebier became a director. NBB
Feb 16, 2011 New establishment in Boechout. KBO
Feb 16, 2011 Start of the company according to the CBE. KBO

In short

From € 144,233 profit in 2022 to € 137,007 profit in 2025.

Paid € 152,443 in corporate taxes since 2022.

Best year ever: 2022, with € 144,233 profit.

Original PDFs at the National Bank ↗

Management

Kaatje Bytebier

Esmoreit De Neef

LIBRA PHARMA

Bytebier Kaatje 100%

Apotheek Sint Bavo 100%

Behind LIBRA PHARMA are Kaatje Bytebier and Esmoreit De Neef. It owns 100% of Bytebier Kaatje and 100% of Apotheek Sint Bavo itself.

Directors

According to the 2025 annual accounts

Kaatje Bytebier

Director

since 2023

Esmoreit De Neef

Director

Also active at: BYTEBIER KAATJE, APOTHEEK SINT BAVO

since 2024

Establishments

Establishment units

Physical locations of this company

Registered office

Vremdesesteenweg 259

2531 Boechout

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

BYTEBIER KAATJE same network

€ 638,501 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0833.903.555

VAT number

BE 0833.903.555

Registered office

Vremdesesteenweg 259, 2531 Boechout

Names & denominations

LIBRA PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 February 2011

Peppol

Active · Active since 18 Sept 2026

Activities · NACE

Detailhandel in farmaceutische producten

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

LIBRA PHARMA

Warning lights

Financials

What happened to LIBRA PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions